This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.
Signing of the informed consent form;
Male or female, aged 18-75 years;
Patients with lung nodules confirmed by CT examination;
Good preoperative pulmonary function cooperation and complete reporting;
Poor preoperative pulmonary function cooperation or missing reports;
Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission;
The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month;
Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.);